Financial Data and Key Metrics Changes - Fourth quarter revenue increased by 12% to $269 million, while full year revenue rose by 14% to $912 million, primarily driven by growth at existing centers and new center additions [18] - Fourth quarter net income per diluted share increased by $3.51 to $4.66, and full year net income per diluted share increased by $3.09 to $4.89 [18] - Fourth quarter adjusted net income per diluted share increased by $0.51 to $1.65, and full year adjusted net income per diluted share increased by $0.80 to $2.42 [19] - Operating cash flow for the fourth quarter was $52 million, totaling $117 million for the full year [19] - The company ended the quarter with $405 million in cash and investments, allowing for continued investments in profitable growth [19] Business Line Data and Key Metrics Changes - The Inspire 5 system demonstrated superiority over Inspire 4, with a significant reduction in surgical time and improved inspiratory overlap, leading to a 79.5% responder rate in the Singapore study [11] - Approximately 10,000 Inspire 5 procedures were performed in 2025, providing a basis for professional reimbursement [9] - The company is nearing completion of manufacturing the Inspire 4 systems but has sufficient inventory for centers that may continue using it [9] Market Data and Key Metrics Changes - The company is actively engaging with key government agencies and physician societies regarding the coding of the Inspire 5 procedure, transitioning to CPT code 64582 with a -52 modifier [6][7] - The coding landscape is expected to impact physician willingness to perform the Inspire 5 procedure, potentially limiting the number of cases [8] - The WISeR program, requiring prior authorization for Medicare cases in six pilot states, has affected procedures in the first quarter [13][14] Company Strategy and Development Direction - The company plans to focus on short and long-term initiatives to address reimbursement challenges and drive consistency across the country [8] - A new CPT code is being pursued for long-term reimbursement clarity, with the goal of minimizing reductions associated with the -52 modifier [10][32] - The company aims to enhance patient access to Inspire therapy through training advanced practice providers and certifying additional surgeons [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the Inspire 5 system's effectiveness and the ability to work with payers to minimize reimbursement reductions [10][102] - The company revised its full year revenue guidance for 2026 to a range of $950 million to $1 billion, reflecting expected impacts from coding uncertainty [20] - Management anticipates sequential improvement in revenue and net income throughout 2026, with the fourth quarter expected to have the highest levels of revenue and profit [24] Other Important Information - The company received FDA approval for 3 Tesla MRI compatibility, enhancing the product's appeal [14] - The Inspire 6 product development program will include features for sleep detection and auto activation, aimed at maximizing therapy adherence [15] Q&A Session Summary Question: Clarity on physician fee with Gen 5 using the 82 code and -52 modifier - Management indicated that clarity on the physician fee is expected as they work with MACs and commercial payers to drive consistency [30] Question: Pathway forward for Gen 5 and pursuing a dedicated code - Management confirmed the pursuit of a new CPT code, emphasizing that the -52 modifier is not a long-term solution [32] Question: Specifics on revenue guidance revision related to reimbursement landscape - Management clarified that the primary reason for revenue reduction is coding uncertainty, with the WISeR program causing some disruption [38] Question: Feedback from physicians regarding the -52 modifier - Management noted that most physicians are in private practice, and those in academic centers are less impacted by the fee reduction [40] Question: Impact of the WISeR program on procedures - Management acknowledged the challenges posed by the WISeR program but expressed confidence in their centers' preparedness for audits [90] Question: Expectations for commercial payers and coding transitions - Management indicated that while commercial payers currently allow billing under 64568, they expect a transition to 64582 with the -52 modifier over time [73]

Financial Data and Key Metrics Changes - Fourth quarter revenue increased by 12% to $269 million, and full year revenue increased by 14% to $912 million, primarily driven by growth at existing centers and new center additions [18][19] - Fourth quarter net income per diluted share increased from $3.51 to $4.66, while full year net income per diluted share increased from $3.09 to $4.89 [18] - Fourth quarter operating cash flow was $52 million, bringing the full year total to $117 million [19] Business Line Data and Key Metrics Changes - The Inspire V system demonstrated superiority over Inspire IV, with a 79.5% responder rate in the Singapore study compared to 66% in the STAR phase III pivotal trial [11] - CPT code 64568 was used for approximately 10,000 Inspire V procedures in 2025, providing a basis for professional reimbursement [9] Market Data and Key Metrics Changes - The company is revising its full year revenue outlook for 2026 to a range of $950 million to $1 billion, reflecting expected impacts from coding uncertainty and physician reimbursement rates [20] - The company anticipates a net loss in the first quarter of 2026 due to revenue expectations and higher operating expenses [23] Company Strategy and Development Direction - The company is focused on developing a new CPT code for the Inspire V procedure, as the current -52 modifier is not seen as a long-term solution [31][82] - The company plans to enhance patient access to Inspire therapy by training advanced practice providers and certifying additional surgeons [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the Inspire V system's effectiveness and the ability to work with payers to minimize reimbursement reductions [104] - The company is addressing challenges related to the WISeR program, which requires prior authorizations for Medicare cases in six pilot states [15][37] Other Important Information - The company completed $50 million of share repurchases in the fourth quarter, bringing the full year total to $175 million [19] - The company is nearing completion of manufacturing the Inspire IV systems but has sufficient inventory for centers that may choose to continue using them [9] Q&A Session Summary Question: Clarity on physician fee with Gen 5 using the 82 code and -52 modifier - Management indicated that existing policies must be followed and that they are working with MACs and commercial payers to drive consistency in reimbursement [28][29] Question: Pathway forward for Gen 5 and pursuing a dedicated code - Management confirmed they are pursuing a new CPT code and have inventory of Inspire IV available for physicians who wish to continue using it [32] Question: Impact of the WISeR program on revenue guidance - Management clarified that the primary reason for revenue reduction is coding uncertainty, while the WISeR program is causing some disruption [37] Question: Pricing strategy in light of reimbursement changes - Management stated that they expect consistent product pricing going forward, aligning with the current pricing model [60] Question: Clarification on coding and competition - Management emphasized confidence in their technology and the Inspire V system's strong safety profile, while acknowledging some impact from competition [68] Question: Expectations for commercial payers and billing practices - Management noted that commercial payers currently allow billing under 64568, but they expect a transition to 64582 with the -52 modifier over time [72]

Group 1 - The core issue raised by parents in Chengdu is the cancellation of unified assessment exams for high school grades one and two, which they believe is essential for objectively measuring student performance and preparing for college entrance exams [1][2] - The Chengdu Education Bureau's response indicates that the cancellation aligns with the Ministry of Education's regulations prohibiting regional or inter-school exams for non-graduating grades [1][2] - The rationale for this decision includes reducing student stress related to exam rankings, allowing schools to tailor assessments to their specific student needs, and enhancing the capacity for schools to create their own exam content [2][1] Group 2 - Concerns were raised about environmental pollution from an open construction site operated by a local company in Aba, which has been reported to cause dust and noise pollution [2][4] - The Aba Ecological Environment Bureau confirmed that the company is undergoing technical upgrades and plans to implement a closed production line by April 2026, following environmental regulations [4][2] Group 3 - A query was made regarding the possibility of applying for special disease status for bipolar disorder, with concerns about the high costs of hospitalization [5] - The response from the Guang'an Medical Insurance Bureau clarified that bipolar disorder can be registered as a chronic special disease, but the reimbursement rate for hospitalization will not be increased, with a cap of 5,000 yuan per year for outpatient treatment [5][5] Group 4 - A request was made for the establishment of direct bus routes from Hongya to nearby cities to enhance tourism, but the local transportation authority indicated that current conditions do not support this initiative [6] - The authority plans to optimize existing bus services and increase frequency during peak travel times to improve passenger experience [6][6]

Summary of Glaukos Conference Call Company Overview - **Company**: Glaukos Corporation - **Products Discussed**: Epioxa and iDose - **Industry**: MedTech, specifically focused on ophthalmic therapies Key Points Epioxa Pricing and Market Dynamics - Epioxa pricing was established after extensive research and consideration of value for patients, providers, and the payer system [5][6] - The company aims to maximize patient awareness and provider education, which is costly but essential for accessing therapies [7][8] - There are approximately 5 million cataract procedures annually in the U.S., but only about 10,000 patients are currently treated with FOTREXA, indicating a significant opportunity for Epioxa [6][9] - The gross-to-net dynamics for Epioxa include: - A 23% statutory discount for Medicaid patients [11] - A similar discount for sales to 340B public hospital systems [11] - Coverage of out-of-pocket costs for commercial patients to ensure access [12][13] Physician Reactions and Market Access - Initial physician feedback on Epioxa pricing has been mixed, with some expressing shock and unrest [15] - The company emphasizes that pricing decisions were made with patient access as a priority, and they are prepared to engage with physicians to explain their rationale [15][16] - The reimbursement landscape for Epioxa is expected to be non-linear, differing from the iDose experience due to the patient demographics and the number of insurance plans involved [19][20] Patient Volume and Market Potential - The U.S. market for Epioxa is estimated to have around 10,000 patients, with potential to reach 20,000 eyes at peak [23] - The company believes there are significantly more undiagnosed patients with keratoconus, indicating a larger market opportunity [25][26] - The goal is to not only return to previous treatment levels but to expand significantly beyond that [25][26] Comparison with iDose - The peak sales opportunity for iDose is viewed as larger than Epioxa due to a larger patient population (21 million potential ocular hypertensive and glaucomatous eyes) [27][28] - iDose is expected to benefit from a more established market and clearer treatment guidelines compared to Epioxa, which is in a rare disease category [21][22] Reimbursement and Market Access Challenges - The company is confident in the long-term access for iDose despite potential hurdles from the CAC (Coverage Advisory Committee) discussions [29][30] - The reimbursement process is complex, with a need for extensive data to support market access [30][31] - The company is optimistic about the potential for Medicare Advantage plans to cover iDose, which could expand access significantly [34][36] Future Outlook - The company is focused on driving incremental utilization in both commercial and Medicare Advantage populations [56][57] - There is a belief that the dynamics of patient access will improve over time as the company continues to engage with payers and physicians [35][36] Additional Insights - The company acknowledges the challenges of competing for operating room time during peak cataract surgery seasons, which may impact iDose sales [44][45] - The management is cautious about setting revenue expectations, considering various scenarios for both Epioxa and iDose [50][52] This summary encapsulates the key discussions and insights from the Glaukos conference call, highlighting the company's strategic focus on pricing, market access, and future growth opportunities in the ophthalmic therapy space.